The Role of Genipin and Geniposide in Liver Diseases: A Review

Sheng-xi Meng1,2, Jing-hua Peng1,2, Qin Feng1,2, Jian-mei Cao4 and Yi-yang Hu1,5*

1Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Key Laboratory of Liver and Kidney Diseases (Shanghai University of Traditional Chinese Medicine), Ministry of Education, Shanghai 201203, China
3E-Institute of Traditional Chinese Internal Medicine of Shanghai Municipal Education Commission, Shanghai 201203, China
4Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
5Shanghai Key Laboratory of Traditional Chinese Clinical Medicine

Abstract

Liver disease is characterized by inflammation and/or tissue damage that is serious enough to impair hepatic function. Tens of millions of patients are affected by liver diseases worldwide. Geniposide is an iridoid glycoside compound isolated from Gardenia fruits which has been used for many years in Chinese medicine for the treatment of hepatic disorders and inflammatory diseases. Genipin, the metabolite of geniposide, is a natural product present in fruit of Gardenia jasminoides. The relative bioactivity of genipin and geniposide has been widely reported in many studies and the potential application of these compounds in the treatment of liver diseases has come to light. This review summarizes current findings on the use of geniposide and genipin in the treatment of liver disease.

Keywords: Geniposide; Genipin; Liver diseases

Introduction

Liver disease is associated with hepatic inflammation, tissue damage and altered liver function, and affects tens of millions of patients worldwide [1]. Geniposide (Figure 1 left) is one of the main iridoid glycosides isolated from Gardenia fruits and has been used for many years in Chinese medicine for treatment of hepatic disorders and inflammatory diseases [2]. Genipin (Figure 1 right), the metabolite of geniposide, is a natural product present in fruit of Gardenia jasminoides. Previous studies have shown that geniposide is transformed to genipin in the bowel, indicating that it may be the major form of geniposide in blood [3–6]. Geniposide is hydrolyzed to aglycone genipin by beta-D-glycosidases which are bacterial enzymes found in the intestines and the liver [7,8] (Figure 2).

Numerous studies have been undertaken to investigate the biological activity of genipin and geniposide, including its effect on protein modulation [9–11], as well as its anti-inflammatory [5,12,13], anti-oxidative [5,14], immunosuppressive [15], anti-thrombotic [16], anti-angiogenic [5], anti-tumor [17–19] and neuroprotective effects [20–23].

Metabolism and Pharmacokinetics

The pharmacokinetics of geniposide, were investigated in a study that simultaneously estimated geniposide and genipin levels in mouse plasma after oral administration of Gardenia fruit [24]. Other studies have described the pharmacokinetics of geniposide after intravenous [25], and oral administration of Yin-Zhi-Ku decoction [26].

**Figure 1:** Structure of Geniposide (left) and Genipin (right).
Geniposide is one of the major iridoid glucosides in Gardenia fruit. It is hydrolyzed in rat intestine by beta-D-glucosidases to form an aglycone genipin compound with choleric properties [19]. Studies have shown that geniposide is not hydrolyzed by rat liver homogenate, even though it contained beta-D-glucosidase and esterase activities. Thus, beta-D-glucosidases in intestinal bacteria seems to be an absolute requirement for its choleric action.

Crude extract of Eubacterium spp. A-44 is a human intestinal anaerobe that has been shown to hydrolyze geniposide. The human anaerobe Ruminococcus spp. PO1-3, does not share this property, even though both extracts share beta-D-glucosidase activity for p-nitrophenyl beta-D-glucopyranoside. Moreover, only one of its three beta-D-glucosidases from Eubacterium spp. A-44 and neither of the two beta-D-glucosidases from Ruminococcus spp PO1-3 hydrolyzed geniposide to genipin. Carboxylesterases from Eubacterium spp. A-44 in pig liver were unable to hydrolyze geniposide to geniposidic acid, but they did hydrolyze genipin to an aglycone of geniposidic acid. These findings indicate that geniposide is first hydrolyzed to genipin by beta-D-glucosidases, and is subsequently hydrolyzed to the aglycone of geniposidic acid by esterases. Thus, following oral administration of geniposide, genipin is produced in the intestine, absorbed into the circulation and transported to the liver where it acts as a choleric [7].

In 2004, it was verified that geniposide is converted to genipin by intestinal bacteria and that genipin is transported to the liver via portal circulation and subjected to conjugation (mainly with glucuronides). Thin-layer and/or high performance liquid chromatography (HPLC) indicates that about 20% of infused genipin is secreted into the bile as the main metabolite 1-O-β-D-glucuronide (Figure 3). Unconjugated genipin accounts for only 2% of the concentration of genipin-1-O-β-D-glucuronide. The other unidentified metabolites are present in bile in small amounts [27]. Genipin sulfate was identified as the major metabolite in the circulation following oral administration of genipin or Gardenia fruit decoction to rats. The parent forms of genipin and geniposide were undetectable [28].

**Effects on Liver Disease**

**Chronic liver injury**

Chronic liver injury is a common condition associated with various liver diseases, which often progress to fibrosis, cirrhosis, or even hepatocellular carcinoma [29].

Kang et al. [9] investigated the effects of geniposide and G. jasminoides crude fruit extract on liver cytochrome P-450 (P-450)-dependent mono-oxygenases, glutathione and glutathione S-transferase in rats treated orally with the iridoid glycoside or fruit extract for 4 days. Both treatments decreased serum urea nitrogen levels and increased the liver to body weight ratio. Total hepatic glutathione content and hepatic cytosolic glutathione S-transferase activity were also increased.

Geniposide and G. jasminoides decreased cytochrome P-450 levels and reduced benzo-[a]-pyrene hydroxylation, 7-ethoxycoumarin O-deethylation, and erythromycin N-demethylation activity in liver microsomes. However, there was no effect on aniline hydroxylation activity. Neither product had any effect on glutathione content or monoxygenase activity in kidney microsomes. Immunoblotting analyses of liver microsomal proteins using mouse monoclonal antibody 2-13-1 to rat P4503A1/2 revealed that geniposide and G. jasminoides crude extract decreased the intensity of a cytochrome P450 3A-immunorelated protein. These findings suggest that geniposide from G. jasminoides acts by inhibiting a P4503A monooxygenase and the increasing glutathione content in rat liver.

Shang Xintao et al. [30] studied the therapeutic effects of geniposide on chronic liver injury induced by carbon tetrachloride (CCL4) in rats. Both CCL4, and soybean oil suspension were fed to rats twice a week for 9 weeks, to produce a model of chronic liver injury. The rats were given different doses of geniposide daily for 4 weeks. Twelve hours after the last dose, AST, ALT, AKP, NO were measured in serum and SOD, MDA, HYP, CAT, and GSH was evaluated in liver tissue. The study reported improvements in pathological indicators of liver injury in serum and liver tissue, at the 100 mg/kg dose level. These findings provided evidence to suggest that geniposide was effective in preventing chronic liver injury induced by CCl4 in rats.

**Acute liver injury**

Acute liver injury is a complex process involving many factors. Its main characteristics are hepatocyte necrosis or apoptosis, hepatocyte degeneration, hepatocyte steatosis, biliary silt lesions and hepatocyte inflammatory reactions.

Yamamoto et al. [31] demonstrated that the Chinese herbal medicine, Inchin-ko-to (ICKT), inhibited hepaticcyte apoptosis induced by transforming growth factor beta 1 in vitro. The same workers investigated whether ICKT or its ingredients (genipin) inhibited Fas-mediated liver apoptosis in vivo. They found that genipin, an intestinal...
bacterial metabolite of geniposide was a major ingredient in the active principle of ICKT. Genipin was shown to suppress Fas-mediated apoptosis in primary-cultured murine hepatocytes. It also inhibited the activation of caspase 3 and 8 in liver homogenates, and reduced triangle uppsi (m) levels in hepatocytes isolated from Jo2-treated mice. Other studies have shown that genipin enhances resistance to Ca2+-induced MPT in mouse liver mitochondria. Taken together, these findings suggest that the anti-apoptotic activity of genipin is mediated by interference with MPT and that this may be a possible mechanism for the therapeutic effects of ICKT.

In other studies, [32] geniposide suppressed AST and ALT activity and prevented the decreased glutathione (GSH) levels that accompanied administration of CCl4 to mice. These findings suggest that a two-fold biochemical mechanism underlies the hepatic protective effect of geniposide. Geniposide reduces the production of the harmful CCl4 radical by decreasing the activities of CYP450 2E1, and at the same time strengthens the ability of GSH system to eliminate free radicals by increasing the activity of glutathione reductase and glutathione S-transferase.

**Alcoholic liver disease**

Alcoholic liver disease (ALD) is responsible for a large proportion of all liver diseases worldwide [33]. Acute alcoholic liver injury is a severe form of acute hepatocyte injury associated with significant morbidity and mortality. Prognostic criteria have been developed to help predict disease severity, but its treatment remains a significant challenge [34].

Fu et al. [35] investigated hepatoprotective effects of geniposide on acute alcoholic liver injury in mice. They showed that geniposide reduced the mortality rate, prolonged survival and decreased serum AST and ALT activity. MDA production in the liver was reduced and pathological changes were less severe. Based on these findings, geniposide appears to have a hepatoprotective effect in acute alcoholic liver injury in mice.

**Bile secretion, liver injury and cholestasis**

Genipin, the major ingredient in ICKT [7], shows marked choleretic activity [36]. Considerable evidence [36] suggests that genipin exerts its choleretic function in a bile acid-independent way by modulating glutathione (GSH) levels in the liver.

Shoda et al. [27] reported a 230% increase in bile flow following administration of genipin to rats. Biliary secretion of bilirubin conjugates increased by 513% and GSH secretion was reduced by 336%. These changes were not present in cells cultured with geniposide, which exerted more significant effects than crocetin.

**Chronic hepatitis**

Chronic viral hepatitis is a major public health issue worldwide [40]. Mase et al. [41] investigated the effects of the active ingredients of inchinkoto (ICKT) on liver injury and cytokine production in vivo (biochemical markers of liver injury and cytokine levels in serum) and in vitro (cytokine and nitrite production in the cultures of splenocytes and peritoneal macrophages). In these experiments, genipin significantly suppressed IFN-gamma production induced in con A-stimulated splenocyte cultures. This was accompanied by suppression of IL-1beta, IL-6, and IL-12p70 synthesis, together with decreased nitrite release from IFN-gamma-stimulated macrophages. These results suggested that genipin may contribute to the protective effects of ICKT against conA hepatitis by modulating cytokine production. These observations were supported by Zhang et al. [42] who also demonstrated that geniposide exhibited significant anti-HCV entry and anti-infectivity activity.

**Liver fibrosis**

Liver fibrosis results from excessive accumulation of extracellular matrix (ECM) proteins, and is a major cause of chronic liver disease. Advanced hepatic fibrosis induced by chronic liver inflammation eventually progresses to cirrhosis [43-46]. Cirrhosis affects hundreds of millions of patients worldwide [44]. In the USA and Europe, it is the most common nonneoplastic cause of death among hepatobiliary and digestive diseases. The condition is also associated with the development of primary liver cancer [47-49].

Inchin-ko-to (TJ-135) is a herbal medicine used for treatment of icteric patients with cirrhosis. Inao et al. [50] investigated the anti-fibrogenic activity of TJ-135 in stellate cell activation. Liver fibrosis was induced in rats by repeated injections of CCL4 or pig-serum. Oral administration of TJ-135 reduced mortality and decreased the extent of liver necrosis and fibrosis. Similar improvements were reported in rats given pig-serum. DNA synthesis of stellate cells activated in vitro, after isolation from normal rat liver, was decreased in a dose-related manner after exposure to TJ-135. This was accompanied by a decrease in smooth muscle alpha actin expression and contractility. These changes were not apparent in cells cultured with geniposide, which is an iridoid compound of TJ-135. Genipin markedly decreased stellate cell activation without affecting synthesis of proteins other than collagen. These results indicate that TJ-135 may have a therapeutic role in the treatment of liver fibrosis and portal hypertension. Its effects are...
secondary to suppression of activated hepatic stellate cell function by genipin (the absorbed form of its component).

**Nonalcoholic fatty liver disease**

Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and is the most common cause of chronic liver disease [51-56], present in 25 to 50% of diabetic patients [57]. NAFLD encompasses a continuum of pathological changes. Initially, triglycerides accumulate in hepatocytes causing steatosis. This can lead to steatohepatitis (NASH), which is characterized by chronic inflammation, fibrosis and necrosis [58]. Cirrhosis, develops in 20% of patients with NASH [59] and is a risk factor for hepatocellular carcinoma (HCC), which is the third most common cause of cancer death worldwide [55,58]. Disturbingly, HCC also can form in the setting of NASH without a background of cirrhosis [60,61]. Lifestyle changes and weight loss are difficult to achieve in most patients, highlighting the urgent need for an effective pharmacologic treatment for NAFLD.

Ma et al. [62] investigated the effects of geniposide during the early phase of fibrogenesis in an animal model of NASH. They showed that geniposide improved liver histology by reducing the elevated liver index (liver weight/body weight), and decreasing serum ALT and AST activity. These changes were accompanied by decreases in total cholesterol, triglycerides and fatty acids in serum and liver. Geniposide also increased serum insulin levels and decreased serum tumour necrosis factor-α levels in high-fat diet rats. Expression of CYP2E1 was reduced and peroxisome proliferator-activated receptor-α (PPARα) expression was increased. These changes were thought to be associated with increased superoxide dismutase and decreased malondialdehyde levels in the liver. The underlying mechanism by which geniposide protects against hepatic steatosis may, therefore, be associated with its antioxidant actions its ability to regulate adipocytokine release and normalization of PPARα expression.

Lin et al. [63] investigated the effect of genipin and Vitamin E (VitE) in non-alcoholic fatty liver disease. They reported that genipin in combination with VitE increased mitochondrial membrane potential and markedly relieved adipose degeneration in liver cells. Shi et al. [64] studied the anti-obesity effects of geniposide in L-monosodium glutamate (MSG)-induced obese mice. In these experiment geniposide inhibited food intake, decreased body weight and reduced blood levels of triglycerides and cholesterol.

Based on the current pre-clinical evidence, Samson and Bajaj [65] have shown that glucagon-like peptide-1 (GLP-1) analogues and DPP4 inhibitors can improve hepatic steatosis. It is thought that GLP-1 and its analogues activate multiple hepaticocyte signal transduction pathways, with both AMP-activated protein kinase and Akt being proposed as key players in the prevention of hepatic steatosis. Interestingly, it has been shown that geniposide acts as a novel and selective agonist for GLP-1 receptors (GLP-1R) [63] providing further evidence of its potential role in the treatment of NASH.

**Fulminant hepatic failure**

Fulminant hepatic failure is a life-threatening clinical syndrome that results in hepaticocyte death. It is induced by viruses, alcohol or hepatotoxic agents. The prognosis is poor, and to date the only effective therapy is liver transplantation. Conventional medical therapies are only effective in about 10% of patients [66,67].

Genipin has been shown to have marked anti-inflammatory and anti-angiogenic effects and inhibit both lipid peroxidation and nitric oxide production [5]. It also suppresses Fas-induced hepatocyte apoptosis and reduces lethality associated with fulminant hepatic failure [30]. Takeuchi et al. [68] explored the mechanism of action of genipin on acute liver injury and concluded that it improved acute liver dysfunction by suppressing of TNF-alpha production.

Recent studies have shown that genipin, acts as a pharmacological inhibitor of uncoupling protein 2, preventing GalN/LPS-induced ATP reduction, SAMP-activated protein kinase, and apoptosis [69] (Figure 4). Kim et al. [70] examined the effects of genipin on d-galactosamine (GalN) and lipopolysaccharide (LPS)-induced hepatic apoptosis and liver failure [71]. Genipin was found to protect against GalN/LPS-induced liver injury, thereby preventing oxidative stress, apoptosis and NF-κB nuclear translocation, and nuclear p-c-Jun expression. This study provides evidence to suggest that genipin may be useful as a potential pharmacological alternative for the prevention of hepatic failure (Figure 4).

**Hepatocellular carcinoma**

Hepatocellular carcinoma (HCC) is an extremely malignant human cancer with high metastatic potential. HCC accounts for over 85% of all liver cancer cases [72] and is newly diagnosed worldwide in more than half of million people annually [73]. HCC is the fifth most common malignant tumor in men and the seventh most common in women [72]. It is the third most common cause of cancer mortality worldwide with incidence rates increasing annually [74]. Despite the provision of different therapeutic approaches, the prognosis of HCC remains poor due to the high recurrence and metastatic rates [75,76]. Currently there are no effective chemotherapeutic agents that are capable of preventing metastasis.

Genipin and geniposide have been shown to induce apoptosis in hepatoma cells Hep3B, cervical cancer cells, HeLa cells, prostate cancer cells PC3 and C6 glioma [77-80]. Previous studies have also reported anti-migration and anti-invasion effects of genipin. Genipin has been shown to suppress alpha-TN4 lens epithelial cells and subconjunctival fibroblast migration induced by TGF-β [81,82].

Hsu et al. [17] investigated the antitumor effects geniposide and geniposidic acid in mice and found that both agents decreased damage to the hematologic tissue after high dose irradiation. Wang et al. [83] 2010 investigated the anti-metastatic effect of genipin and found that it suppressed the motility and invasiveness of HepG2 and MHCC97L.

![Figure 4: Schematic diagram for genipin inhibition of GalN/LPS-induced hepatocyte apoptosis.](image-url)
at non-toxic doses. These effects were possibly associated with an inhibitory effect of genipin on intracellular MMP-2 activity. They also demonstrated the potential of genipin to suppress HCC metastasis, and indicated that the p38/TIMP-1/MMP-2 pathway may be a key mechanism of this anti-metastatic effect (Figure 5). Kim et al. [77] 2005 demonstrated that genipin induces apoptotic cell death in FaO rat hepatoma cells and human hepatocarcinoma Hep3B cells, as evidenced by morphological cellular changes, caspase activation and release of cytochrome C. These findings suggest that genipin induced apoptosis in hepatoma cells is mediated by NADPH oxidase-dependent generation of reactive oxygen species (ROS), resulting in downstream activation of c-Jun NH2-terminal kinase (JNK).

Detoxication

Wang et al. [84] examined the effects of geniposide pretreatment on hepatic aflatoxin B1 (AFB1)-DNA binding and AFB1 hepatotoxicity in rats. Pretreatment with geniposide 10 mg/kg/day for 3 consecutive days, resulted in suppression of serum marker enzymes (ALT, AST GGT). It was therefore suggested that geniposide possessed chemopreventive effects on the early acute hepatic damage induced by AFB1.

It was further demonstrated that the protective effect of geniposide on AFB1-induced hepatotoxicity in rats may be due to the hepatic tissue defense mechanisms that enhanced S-transferase (GST) activity for AFB1 detoxication and induced gamma-glutamylcysteine synthetase for GSH biosynthesis. Subsequent experiments [85] investigated the effects of geniposide on AFB1-induced DNA repair synthesis and AFB1 biotransformation in cultured rat hepatocytes. Evaluation of unscheduled DNA synthesis (UDS) indicated that geniposide reduced AFB1-induced DNA repair synthesis in a dose-dependent manner in hepatocyte cultures. Geniposide increased AFB1 metabolism and decreased the formation of aflatoxin M1 (AFM1). The enzyme activities of glutathione S-transferase (GST) and GSH-peroxidase (GSH-Px) in AFB1-treated hepatocyte cultures were both enhanced in the presence of geniposide. Geniposide reduced AFB1-induced DNA repair synthesis by increasing AFB1 detoxication metabolism. These findings provide a possible mechanism for the chemopreventive activity of geniposide.

Kuo et al. [10] investigated the mechanism of action of geniposide on the GST system. Geniposide-induced GST activity was shown to be dose- and time-dependent, and was found to be mediated via the MEK pathway. These results suggest that geniposide-induced detoxication is mediated by increased transcription of GST M1 and GST M2 resulting in enhanced GST activity. The same workers investigated the signaling pathway of geniposide and demonstrated that geniposide-induced GST activity and the expression of GST M1 and GST M2 resulted from its effects on the MEK-1 pathway which were secondary to activation and increased expression of Ras/Raf/MEK-1 signaling mediators [11].

Toxicity

Yamano et al. [86] demonstrated that the conversion of geniposide to genipin is causally associated with the hepatotoxicity of geniposide, and that hepatic non-protein sulphhydryl groups modulate the extent of toxicity. Sato et al. [87] showed that 3 months ingestion of the gardenia yellow powder containing geniposide 2.78% (equivalent to intake of 60 mg/kg/day) was not accompanied by any severe toxic effects.

The LD₅₀ for oral geniposide is 1431.1 mg kg⁻¹. Acute toxicity studies indicate that geniposide at doses of 574 mg kg⁻¹ and higher are associated with hepatic toxicity in rats. The hepatotoxicity generally appeared 24 to 48 h after oral administration and was associated with oxidative stress, decreased total superoxide dismutase activity and increased malondialdehyde concentration in rat livers. Subchronic toxicity studies in rats found no evidence of hepatotoxicity at the doses of 24.3 and 72.9 mg kg⁻¹ given orally for 90 days. Thus, the acute hepatotoxicity of geniposide at high doses was possibly related with oxidative stress, while geniposide at normal doses of 24.3 mg kg⁻¹ were not associated with hepatotoxicity after repeated dosing [88].

Yang et al. [89] studied the hepatotoxic effects in rats with different extracts of Fructus gardeniae. They found that the alcoholic extract and geniposide displayed hepatotoxicity, and that geniposide which was the main extract might be mainly responsible for this. Oral administered genipin 200 mg kg⁻¹ resulted in a 78% mortality rate in rats [27]. Khanal et al. [90] reported that genipin but not geniposide was associated with cytotoxicity. They also demonstrated that human Intestinal microflora (IM) was able to metabolize geniposide genipin, and the resulting biological activity induced apoptosis through ROS/JNK signaling.

Further research is needed to more fully characterize the toxic effects of geniposide and genipin.

Summary and Prospect

In this review, we describe and analyze the hepatoprotective effects of geniposide and its metabolite, genipin in liver disease. Both compounds exert extensive beneficial effects that offer potential therapeutic benefit to patients with liver disease. Ongoing studies are being conducted to further explore these properties. Further studies will be focused on both short- and long-term effects of geniposide and genipin in the treatment of liver disease and will seek to identify more clearly the complex cellular and biochemical mechanisms that underlie the disease processes.

Acknowledgements

This project was supported by grants from the National Natural Science Foundation of China (No 81173404); The Innovative Research Team in Shanghai Universities, Shanghai Municipal Education Commission; and Leading Academic Discipline of Hepatology of State Administration of TCM China (No. 2010ah).

The authors declare that there is no conflict of interest.

References


